Changes of peritoneal transport parameters with time on dialysis: assessment with sequential peritoneal equilibration test



Sequential peritoneal equilibration test (sPET) is based on the consecutive performance of the peritoneal equilibration test (PET, 4-hour, glucose 2.27%) and the mini-PET (1-hour, glucose 3.86%), and the estimation of peritoneal transport parameters with the 2-pore model. It enables the assessment of the functional transport barrier for fluid and small solutes. The objective of this study was to check whether the estimated model parameters can serve as better and earlier indicators of the changes in the peritoneal transport characteristics than directly measured transport indices that depend on several transport processes.


17 patients were examined using sPET twice with the interval of about 8 months (230 ± 60 days).


There was no difference between the observational parameters measured in the 2 examinations. The indices for solute transport, but not net UF, were well correlated between the examinations. Among the estimated parameters, a significant decrease between the 2 examinations was found only for hydraulic permeability LpS, and osmotic conductance for glucose, whereas the other parameters remained unchanged. These fluid transport parameters did not correlate with D/P for creatinine, although the decrease in LpS values between the examinations was observed mostly for patients with low D/P for creatinine.


We conclude that changes in fluid transport parameters, hydraulic permeability and osmotic conductance for glucose, as assessed by the pore model, may precede the changes in small solute transport. The systematic assessment of fluid transport status needs specific clinical and mathematical tools beside the standard PET tests.

Int J Artif Organs 2017; 40(11): 595 - 601




Jacek Waniewski, Stefan Antosiewicz, Daniel Baczynski, Jan Poleszczuk, Mauro Pietribiasi, Bengt Lindholm, Zofia Wankowicz

Article History


Financial support: This work was supported by the National Center for Science, Poland, as the research project N N518407638. Baxter Novum is the result of a grant from Baxter Healthcare to the Karolinska Institutet.
Conflict of interest: Bengt Lindholm is employed by Baxter Healthcare. None of the other authors has financial interests related to this study to disclose.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  • Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw - Poland
  • Military Institute of Medicine, Warsaw - Poland
  • Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm - Sweden

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.